CHELIDONIUM MAJUS

N/A

Manufactured by BM Private Limited

30 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CHELIDONIUM MAJUS

CHELIDONIUM MAJUS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BM Private Limited. The most commonly reported adverse reactions for CHELIDONIUM MAJUS include LACTIC ACIDOSIS, ACUTE KIDNEY INJURY, DRUG INTERACTION, DEPRESSION, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CHELIDONIUM MAJUS.

Top Adverse Reactions

LACTIC ACIDOSIS6 reports
ACUTE KIDNEY INJURY5 reports
DRUG INTERACTION5 reports
DEPRESSION1 reports
DIARRHOEA1 reports
DRUG INEFFECTIVE1 reports
EOSINOPHILIC HEPATITIS1 reports
GAMMA GLUTAMYLTRANSFERASE INCREASED1 reports
GENERAL PHYSICAL HEALTH DETERIORATION1 reports
HEPATOCELLULAR INJURY1 reports
ISCHAEMIA1 reports
JAUNDICE1 reports
PRODUCT USE IN UNAPPROVED INDICATION1 reports
RENAL FAILURE ACUTE1 reports
TREATMENT FAILURE1 reports
TYPE 2 DIABETES MELLITUS1 reports
VOMITING1 reports

Report Outcomes

Out of 11 classified reports for CHELIDONIUM MAJUS:

Serious 100.0%Non-Serious 0.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female6 (60.0%)
Male4 (40.0%)

Reports by Age

Age 765 reports
Age 282 reports
Age 661 reports
Age 721 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CHELIDONIUM MAJUS?

This profile reflects 30 FDA FAERS reports that mention CHELIDONIUM MAJUS. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CHELIDONIUM MAJUS?

Frequently reported terms in FAERS include LACTIC ACIDOSIS, ACUTE KIDNEY INJURY, DRUG INTERACTION, DEPRESSION, DIARRHOEA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CHELIDONIUM MAJUS?

Labeling and FAERS entries often list BM Private Limited in connection with CHELIDONIUM MAJUS. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.